NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
This is a phase II clinical trial using risk-adapted therapy. The treatment is acute lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months. Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone marrow/peripheral blood lymphoma cells involvement at diagnosis for B-lymphoblastic lymphoma.
The Primary Objective of this study is:
To improve the outcome of children with lymphoblastic lymphoma (LL) who have minimal disseminated disease (MDD) equal to or more than 1% at diagnosis by using MDD- and minimal residual disease (MRD)- based risk-adapted therapy.
The Secondary Objectives of this study are:
- To determine event-free and overall survival
- Investigate the relationship between Day 8 MRD and MDD results and EFS
Drug: Erwinia asparaginase
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma|
- Event-free survival (EFS). [ Time Frame: Two years post therapy. ] [ Designated as safety issue: No ]Kaplan-Meier survival curve estimate.
- Overall survival (OS). [ Time Frame: Two years post therapy. ] [ Designated as safety issue: No ]Kaplan-Meier survival curve estimate.
- Percentage of lymphoblastic cells in bone marrow at diagnosis (MDD) and at day 8 of therapy (MRD). [ Time Frame: Two years post day 8. ] [ Designated as safety issue: No ]Cox regression modeling of EFS with MRD and MDD as explanatory variables.
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||May 2027|
|Estimated Primary Completion Date:||May 2027 (Final data collection date for primary outcome measure)|
Patients will undergo treatment as described in the intervention section. Interventions include:
Given orally (PO).
Other Name: PrednisoloneDrug: Vincristine
Given intravenously (IV).
Other Names:Drug: Daunorubicin
Other Names:Drug: PEG-asparaginase
Given intramuscularly (IM) or IV.
Other Names:Drug: Erwinia asparaginase
Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
Other Name: Erwinase®Drug: Doxorubicin
Other Name: Adriamycin®Drug: Cyclophosphamide
Other Name: Cytoxan®Drug: Cytarabine
Given IV or IT.
Other Names:Drug: Thioguanine
Other Name: Purine antimetaboliteDrug: Clofarabine
Other Names:Drug: Methotrexate
Given IV or IT.
Other Names:Drug: Mercaptopurine
Other Names:Drug: Dexamethasone
Given PO or IV.
Other Name: Decadron®Drug: Hydrocortisone
Other Name: Cortef®Drug: Etoposide
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01451515
|Contact: Hiroto Inaba, MD,PhDemail@example.com|
|United States, California|
|Rady Children's Hospital San Diego||Recruiting|
|San Diego, California, United States, 92123|
|Contact: Catherine E. Madigan, MD 858-966-5811 firstname.lastname@example.org|
|Principal Investigator: Catherine E. Madigan, MD|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Hiroto Inaba, MD,Ph.D 866-278-5833 email@example.com|
|Principal Investigator: Hiroto Inaba, MD,Ph.D|
|Principal Investigator:||Hiroto Inaba, MD,PhD||St. Jude Children's Research Hospital|